Columbia University scientists study tumor revertants as possible new approach to cancer therapy.
Andrea Califano and his investigative team discover a molecular signaling mechanism underlying a specific type of highly aggressive breast cancer.
KEYTRUDA is an immunotherapy that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, helping the immune system to help detect and fight cancer cells.
The Columbia Combined Cancer Panel has been granted full approval by the New York State Department of Health.
Dr. Naiyer Rizvi, director of thoracic oncology at CUMC, offers updates on immune checkpoint inhibitors in certain forms of lung cancers.
Columbia scientists have created new decoy drugs that can intercept the deceptive growth signals that cancer cells send out.